Anti-HIV-1 HSPC-based gene therapy with safety kill switch to defend against and attack HIV-1 infection

By sjmartinez • June 13, 2025

Guo Q, Parikh K, Zhang J, Brinkley A, Chen G, Jakramonpreeya N, Zhen A, An DS. Anti-HIV-1 HSPC-based gene therapy with safety kill switch to defend against and attack HIV-1 infection. Mol Ther Methods Clin Dev. 2025 May 15;33(2):101486. doi: 10.1016/j.omtm.2025.101486. PMID: 40503012; PMCID: PMC12152878.

Tags: C46 membrane-anchored HIV-1 fusion inhibitor, CCR5 short hairpin RNA, CD4-based anti-HIV-1 chimeric antigen receptor, cetuximab-mediated in vivo negative selection, Hematology/Oncology, hematopoietic stem/progenitor cell-based gene therapy, HIV-1, HSPC, huEGFRt, humanized mouse, Publications, truncated human EGFR

Related Posts

Results from a Phase II Single Arm Trial Evaluating the Safety and Efficacy of Anhydrous Enol-Oxaloacetate on Improving Cognitive Complaints in Breast Cancer Survivors

Ganz PA, Van Dyk K, Crespi CM, Petersen L, Sedrak MS, Bower JE. Results from a Phase II Single Arm Trial Evaluating the Safety and[...]

Darovasertib and Crizotinib First-Line Treatment for Metastatic Uveal Melanoma: Overall Survival, Efficacy, and Safety From the OptimUM-01 Study

McKean M, Chmielowski B, Butler MO, Carvajal RD, Rodon J, Carlino MS, Kim KB, Wise-Draper TM, Khan S, Salama AKS, Moser J, Ang A, Barrios[...]

Conversational artificial intelligence for geriatric screening: A mixed-methods feasibility study

Naeim A, Cheng J, Spiegel B, Bakshian A, Tetrault E, Mehra M, Amini D, Krut Z, Shang H, Sedrak MS, Bui A, Johnson T, Wang[...]